Suppr超能文献

基于分子病理学抗生素耐药性的根除治疗在中国老年人群中的疗效与安全性

Effect and Safety of Eradication Treatment Based on Molecular Pathologic Antibiotic Resistance in Chinese Elderly People.

作者信息

Gao Chun, Fan Yan-Hua

机构信息

Department of Gastroenterology, China-Japan Friendship Hospital, Beijing, 100029, People's Republic of China.

出版信息

Infect Drug Resist. 2022 Jun 22;15:3277-3286. doi: 10.2147/IDR.S371113. eCollection 2022.

Abstract

BACKGROUND

The elderly people generally have poor tolerance to drugs and an increased risk of adverse effects. Our study was designed to determine the effect and safety of () eradication treatment based on molecular pathologic antibiotic resistance in Chinese elderly people over the age of 60 years.

METHODS

A total of 364 people were retrospectively analyzed, including 113 older people over 60 and 251 young and middle-aged people in the age of 20-59 years. Real-time PCR detection and conventional PCR and sequencing method were used for drug susceptibility testing. As the main outcome measure, the eradication rates (ERs) with their 95% confidence intervals (CIs) were analyzed by intention to treat (ITT) and per protocol (PP). For the safety of therapy, adverse events were analyzed.

RESULTS

For the total people, the resistance rates to clarithromycin (CLR), amoxicillin (AMX), fluoroquinolone (FLQ) and tetracycline (TET) were 65.06%, 7.54%, 61.39% and 20.37%, respectively. After they were divided into two groups, the resistance rates were 62.39% (CLR), 9.09% (AMX), 69.64% (FLQ) and 22.45% (TET) in the 113 older people over 60, and 66.26%, 6.85%, 57.66% and 19.47% in the 251 young and middle-aged people in 20-59. By the ITT analysis, the ERs were 92.04% (95% CI, 86.97-97.10%, n=113) in the older people and 92.43% (95% CI, 89.14-95.73%, n=251) in the young and middle-aged people. By the PP analysis, the ERs were 96.30% (95% CI, 92.68-99.92%, n=108) and 94.69% (95% CI, 91.87-97.52%, n=245), respectively. No significant differences were shown both in the ITT analysis (P=0.896) and in the PP analysis (P=0.517). The three most common adverse events were black stool, dysgeusia and diarrhea, and no serious adverse event was reported.

CONCLUSION

eradication treatment based on molecular pathologic antibiotic resistance showed good effect and safety in Chinese elderly people.

摘要

背景

老年人通常对药物耐受性差,不良反应风险增加。我们的研究旨在确定基于分子病理抗生素耐药性的()根除治疗对60岁以上中国老年人的疗效和安全性。

方法

回顾性分析364人,其中包括113名60岁以上老年人和251名20 - 59岁的中青年。采用实时荧光定量PCR检测及常规PCR和测序方法进行药敏试验。作为主要结局指标,通过意向性分析(ITT)和符合方案分析(PP)分析根除率(ERs)及其95%置信区间(CIs)。对于治疗安全性,分析不良事件。

结果

总体人群中,对克拉霉素(CLR)、阿莫西林(AMX)、氟喹诺酮(FLQ)和四环素(TET)的耐药率分别为65.06%、7.54%、61.39%和20.37%。分为两组后,113名60岁以上老年人中对CLR、AMX、FLQ和TET的耐药率分别为62.39%、9.09%、69.64%和22.45%,251名20 - 59岁中青年中分别为66.26%、6.85%、57.66%和19.47%。通过ITT分析,老年人的根除率为92.04%(95%CI,86.97 - 97.10%,n = 113),中青年的根除率为92.43%(95%CI,89.14 - 95.73%,n = 251)。通过PP分析,根除率分别为96.30%(95%CI,92.68 - 99.92%,n = 108)和94.69%(95%CI,91.87 - 97.52%,n = 245)。ITT分析(P = 0.896)和PP分析(P = 0.517)均未显示出显著差异。三种最常见的不良事件为黑便、味觉障碍和腹泻,未报告严重不良事件。

结论

基于分子病理抗生素耐药性的根除治疗在中国老年人中显示出良好的疗效和安全性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a8b6/9234187/15ab6ace44a3/IDR-15-3277-g0001.jpg

相似文献

引用本文的文献

4
Helicobacter pylori Eradication Treatment in Older Patients.老年患者的幽门螺杆菌根除治疗。
Drugs Aging. 2024 Feb;41(2):141-151. doi: 10.1007/s40266-023-01090-w. Epub 2024 Feb 10.
8
Focusing on infection in the elderly.关注老年人的感染问题。
Front Cell Infect Microbiol. 2023 Mar 10;13:1121947. doi: 10.3389/fcimb.2023.1121947. eCollection 2023.

本文引用的文献

6
Effect of Temperature on Metronidazole Resistance in .温度对……中甲硝唑耐药性的影响
Front Microbiol. 2021 May 19;12:681911. doi: 10.3389/fmicb.2021.681911. eCollection 2021.
7
Helicobacter pylori Infection.幽门螺杆菌感染。
Gastroenterol Clin North Am. 2021 Jun;50(2):261-282. doi: 10.1016/j.gtc.2021.02.001.
10
Helicobacter pylori: an evolutionary perspective.幽门螺杆菌:进化视角。
Histopathology. 2021 Jan;78(1):39-47. doi: 10.1111/his.14245.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验